These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 35313945)

  • 1. Reductive TCA cycle catalyzed by wild-type IDH2 promotes acute myeloid leukemia and is a metabolic vulnerability for potential targeted therapy.
    Zeng P; Lu W; Tian J; Qiao S; Li J; Glorieux C; Wen S; Zhang H; Li Y; Huang P
    J Hematol Oncol; 2022 Mar; 15(1):30. PubMed ID: 35313945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells.
    Kim Y; Jeung HK; Cheong JW; Song J; Bae SH; Lee JI; Min YH
    Yonsei Med J; 2020 Sep; 61(9):762-773. PubMed ID: 32882760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IDH2 inhibition in AML: Finally progress?
    Stein EM
    Best Pract Res Clin Haematol; 2015; 28(2-3):112-5. PubMed ID: 26590767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wild-type IDH2 is a therapeutic target for triple-negative breast cancer.
    Li JJ; Yu T; Zeng P; Tian J; Liu P; Qiao S; Wen S; Hu Y; Liu Q; Lu W; Zhang H; Huang P
    Nat Commun; 2024 Apr; 15(1):3445. PubMed ID: 38658533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome-scale integrated analysis to identify prospective molecular mechanisms and therapeutic targets in isocitrate dehydrogenase 2 R140Q-mutated acute myeloid leukemia.
    Huang R; Liao X; Li J; Wei J; Su X; Lai X; Liu B; Zhu F; Huang Y; Li Q
    Oncol Rep; 2019 May; 41(5):2876-2888. PubMed ID: 30896832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition.
    Chen C; Liu Y; Lu C; Cross JR; Morris JP; Shroff AS; Ward PS; Bradner JE; Thompson C; Lowe SW
    Genes Dev; 2013 Sep; 27(18):1974-85. PubMed ID: 24065765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability.
    Wise DR; Ward PS; Shay JE; Cross JR; Gruber JJ; Sachdeva UM; Platt JM; DeMatteo RG; Simon MC; Thompson CB
    Proc Natl Acad Sci U S A; 2011 Dec; 108(49):19611-6. PubMed ID: 22106302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IDH2 and NPM1 Mutations Cooperate to Activate Hoxa9/Meis1 and Hypoxia Pathways in Acute Myeloid Leukemia.
    Ogawara Y; Katsumoto T; Aikawa Y; Shima Y; Kagiyama Y; Soga T; Matsunaga H; Seki T; Araki K; Kitabayashi I
    Cancer Res; 2015 May; 75(10):2005-16. PubMed ID: 25795706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the
    Amaya ML; Pollyea DA
    Clin Cancer Res; 2018 Oct; 24(20):4931-4936. PubMed ID: 29769206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes.
    Matre P; Velez J; Jacamo R; Qi Y; Su X; Cai T; Chan SM; Lodi A; Sweeney SR; Ma H; Davis RE; Baran N; Haferlach T; Su X; Flores ER; Gonzalez D; Konoplev S; Samudio I; DiNardo C; Majeti R; Schimmer AD; Li W; Wang T; Tiziani S; Konopleva M
    Oncotarget; 2016 Nov; 7(48):79722-79735. PubMed ID: 27806325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.
    Nassereddine S; Lap CJ; Haroun F; Tabbara I
    Ann Hematol; 2017 Dec; 96(12):1983-1991. PubMed ID: 29090344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic dysregulation in cancers by isocitrate dehydrogenase 2 (IDH2).
    Nayarisseri A; Bandaru S; Khan A; Sharma K; Bhrdwaj A; Kaur M; Ghosh D; Chopra I; Panicker A; Kumar A; Saravanan P; Belapurkar P; Mendonça Junior FJB; Singh SK
    Adv Protein Chem Struct Biol; 2024; 141():223-253. PubMed ID: 38960475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic
    Yen K; Travins J; Wang F; David MD; Artin E; Straley K; Padyana A; Gross S; DeLaBarre B; Tobin E; Chen Y; Nagaraja R; Choe S; Jin L; Konteatis Z; Cianchetta G; Saunders JO; Salituro FG; Quivoron C; Opolon P; Bawa O; Saada V; Paci A; Broutin S; Bernard OA; de Botton S; Marteyn BS; Pilichowska M; Xu Y; Fang C; Jiang F; Wei W; Jin S; Silverman L; Liu W; Yang H; Dang L; Dorsch M; Penard-Lacronique V; Biller SA; Su SM
    Cancer Discov; 2017 May; 7(5):478-493. PubMed ID: 28193778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of High-Affinity Small Molecule Targeting IDH2 for the Clinical Treatment of Acute Myeloid Leukemia.
    Sweta J; Khandelwal R; Srinitha S; Pancholi R; Adhikary R; Ali MA; Nayarisseri A; Vuree S; Singh SK
    Asian Pac J Cancer Prev; 2019 Aug; 20(8):2287-2297. PubMed ID: 31450897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a selective inhibitor of IDH2/R140Q enzyme that induces cellular differentiation in leukemia cells.
    Chen J; Yang J; Wei Q; Weng L; Wu F; Shi Y; Cheng X; Cai X; Hu C; Cao P
    Cell Commun Signal; 2020 Apr; 18(1):55. PubMed ID: 32245484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of de novo lipogenesis by the IDH1 and IDH2-dependent reverse TCA cycle maintains the growth and angiogenic capacity of bone marrow-derived endothelial progenitor cells under hypoxia.
    He Q; Yu T; Chen J; Liang J; Lin D; Yan K; Xie Z; Song Y; Chen Z
    Free Radic Biol Med; 2024 Mar; 213():327-342. PubMed ID: 38281628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Replication Study: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
    Showalter MR; Hatakeyama J; Cajka T; VanderVorst K; Carraway KL; Fiehn O;
    Elife; 2017 Jun; 6():. PubMed ID: 28653623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IDH2/R140Q mutation confers cytokine-independent proliferation of TF-1 cells by activating constitutive STAT3/5 phosphorylation.
    Yang J; Chen J; Chang J; Sun X; Wei Q; Cai X; Cao P
    Cell Commun Signal; 2024 Feb; 22(1):116. PubMed ID: 38347540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wild-type IDH2 protects nuclear DNA from oxidative damage and is a potential therapeutic target in colorectal cancer.
    Qiao S; Lu W; Glorieux C; Li J; Zeng P; Meng N; Zhang H; Wen S; Huang P
    Oncogene; 2021 Sep; 40(39):5880-5892. PubMed ID: 34349242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy for isocitrate dehydrogenase 2 (IDH2)
    Linch DC; Hills RK; Burnett AK; Russell N; Gale RE
    Br J Haematol; 2022 Mar; 196(6):1348-1352. PubMed ID: 34870324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.